• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

源自脐带血的嵌合抗原受体自然杀伤细胞(CAR-NK细胞)主要起源于CD56⁺CD7⁻CD34⁻HLA-DR⁻Lin⁻自然杀伤祖细胞。

CAR-NK cells derived from cord blood originate mainly from CD56CD7CD34HLA-DRLin NK progenitor cells.

作者信息

Wibowo Tansri, Kogue Yosuke, Ikeda Shunya, Yaga Moto, Tachikawa Mana, Suga Makiko, Kida Shuhei, Shibata Kumi, Tsutsumi Kazuhito, Murakami Hiraku, Ueda Yasutaka, Kato Hisashi, Fukushima Kentaro, Fujita Jiro, Ueda Tomoaki, Kusakabe Shinsuke, Hino Akihisa, Ichii Michiko, Imai Chihaya, Okuzaki Daisuke, Kumanogoh Atsushi, Hosen Naoki

机构信息

Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Osaka Research Center for Drug Discovery, Otsuka Pharmaceutical Company, Ltd., Osaka 562-0029, Japan.

出版信息

Mol Ther Methods Clin Dev. 2024 Nov 12;32(4):101374. doi: 10.1016/j.omtm.2024.101374. eCollection 2024 Dec 12.

DOI:10.1016/j.omtm.2024.101374
PMID:39659759
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11629225/
Abstract

Cord blood (CB)-derived chimeric antigen receptor (CAR)-natural killer (NK) cells targeting CD19 have been shown to be effective against B cell malignancies. While human CD56 NK cells can be expanded , NK cells can also be differentiated from hematopoietic progenitor cells. It is still unclear whether CAR-NK cells originate from mature NK cells or NK progenitor cells in CB. Here, we determined that CAR-NK cells were predominantly derived from CD56 NK progenitor cells. We first found that substantial numbers of CD19 CAR-NK cells were produced from CD56 CB mononuclear cells after culture for 2 weeks. Single-cell RNA sequencing analysis of CD56CD3CD14CD19 CB mononuclear cells revealed that these cells could be subdivided into three subpopulations based on the expression of CD34 and human leukocyte antigen (HLA)-DR. NK cells originated primarily from CD34HLA-DR cells. In addition, among the CD34HLA-DR cells, only CD7 cells could differentiate into NK cells. These results indicate that CD56CD7CD34HLA-DR lineage marker (Lin) cells are the major origin of human CB-derived CAR-NK cells, indicating the importance of developing methods to enhance the quality and quantity of NK cells produced from these NK progenitor cells.

摘要

靶向CD19的脐血(CB)来源的嵌合抗原受体(CAR)-自然杀伤(NK)细胞已被证明对B细胞恶性肿瘤有效。虽然人CD56 NK细胞可以扩增,但NK细胞也可以从造血祖细胞分化而来。目前尚不清楚CAR-NK细胞是源自CB中的成熟NK细胞还是NK祖细胞。在这里,我们确定CAR-NK细胞主要源自CD56 NK祖细胞。我们首先发现,在培养2周后,大量的CD19 CAR-NK细胞从CD56 CB单核细胞中产生。对CD56CD3CD14CD19 CB单核细胞进行单细胞RNA测序分析表明,这些细胞可根据CD34和人类白细胞抗原(HLA)-DR的表达分为三个亚群。NK细胞主要源自CD34HLA-DR细胞。此外,在CD34HLA-DR细胞中,只有CD7细胞可以分化为NK细胞。这些结果表明,CD56CD7CD34HLA-DR谱系标志物(Lin)细胞是人类CB来源的CAR-NK细胞的主要来源,这表明开发提高从这些NK祖细胞产生的NK细胞质量和数量的方法具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/11629225/3a9929e7528d/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/11629225/beab801ef09f/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/11629225/02def82978ff/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/11629225/3a9929e7528d/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/11629225/beab801ef09f/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/11629225/02def82978ff/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/11629225/3a9929e7528d/gr2.jpg

相似文献

1
CAR-NK cells derived from cord blood originate mainly from CD56CD7CD34HLA-DRLin NK progenitor cells.源自脐带血的嵌合抗原受体自然杀伤细胞(CAR-NK细胞)主要起源于CD56⁺CD7⁻CD34⁻HLA-DR⁻Lin⁻自然杀伤祖细胞。
Mol Ther Methods Clin Dev. 2024 Nov 12;32(4):101374. doi: 10.1016/j.omtm.2024.101374. eCollection 2024 Dec 12.
2
The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture.在长期骨髓培养中从CD34+/DR-原始祖细胞生成人类自然杀伤细胞。
Blood. 1992 Nov 1;80(9):2182-7.
3
Differential effects of interleukin-3, interleukin-7, interleukin 15, and granulocyte-macrophage colony-stimulating factor in the generation of natural killer and B cells from primitive human fetal liver progenitors.白细胞介素-3、白细胞介素-7、白细胞介素15和粒细胞-巨噬细胞集落刺激因子对源自原始人类胎儿肝脏祖细胞的自然杀伤细胞和B细胞生成的不同作用。
Exp Hematol. 2000 Aug;28(8):961-73. doi: 10.1016/s0301-472x(00)00490-2.
4
A child case of CD34+, CD33-, HLA-DR-, CD7+, CD56+ stem cell leukemia with thymic involvement.1例伴有胸腺受累的CD34+、CD33-、HLA-DR-、CD7+、CD56+干细胞白血病儿童病例。
Leuk Res. 1996 Nov-Dec;20(11-12):983-5. doi: 10.1016/s0145-2126(96)00056-2.
5
[Expression of Th17 and IL-23 in Peripheral Blood and Their Relationship with Immunophenotype in Patients with Acute Myeloid Leukemia].[急性髓系白血病患者外周血中Th17和IL-23的表达及其与免疫表型的关系]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Aug;30(4):1056-1062. doi: 10.19746/j.cnki.issn.1009-2137.2022.04.013.
6
Generation of functional natural killer and dendritic cells in a human stromal-based serum-free culture system designed for cord blood expansion.在一种为脐血扩增设计的基于人基质的无血清培养系统中生成功能性自然杀伤细胞和树突状细胞。
Exp Hematol. 2008 Jan;36(1):61-8. doi: 10.1016/j.exphem.2007.08.031.
7
Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor.用抑制性嵌合抗原受体靶向血液系统恶性肿瘤中的 HLA-DR 缺失。
Mol Ther. 2022 Mar 2;30(3):1215-1226. doi: 10.1016/j.ymthe.2021.11.013. Epub 2021 Nov 18.
8
Phenotype analysis of hematopoietic CD34+ cell populations derived from human umbilical cord blood using flow cytometry and cDNA-polymerase chain reaction.使用流式细胞术和cDNA聚合酶链反应对源自人脐带血的造血CD34+细胞群体进行表型分析。
Blood. 1994 Apr 15;83(8):2103-14.
9
Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56CD16NKp80 and Express KIR2DL2/DL3 and KIR3DL1.由人诱导多能干细胞生成的自然杀伤细胞成熟为 CD56CD16NKp80,并表达 KIR2DL2/DL3 和 KIR3DL1。
Front Immunol. 2021 May 4;12:640672. doi: 10.3389/fimmu.2021.640672. eCollection 2021.
10
Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15.鉴定出一种新型人类脐带血CD34-CD133-CD7-CD45+谱系阴性细胞亚群,该亚群在体外暴露于白细胞介素-15后能够分化为淋巴细胞/NK细胞。
J Immunol. 2003 Sep 15;171(6):2977-88. doi: 10.4049/jimmunol.171.6.2977.

引用本文的文献

1
NK Cells: A Powerful Squad Versus SARS-CoV-2.自然杀伤细胞:对抗新冠病毒的强大力量
Int J Mol Sci. 2025 Jul 6;26(13):6500. doi: 10.3390/ijms26136500.
2
Emerging Role of Chimeric Antigen Receptor-Natural Killer Cells for the Treatment of Hematologic Malignancies.嵌合抗原受体自然杀伤细胞在血液系统恶性肿瘤治疗中的新兴作用。
Cancers (Basel). 2025 Apr 26;17(9):1454. doi: 10.3390/cancers17091454.

本文引用的文献

1
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 B cell tumors: a phase 1/2 trial.同种异体 CD19 特异性 CAR-NK 细胞治疗 CD19 B 细胞肿瘤的安全性、有效性和反应决定因素:一项 1/2 期试验。
Nat Med. 2024 Mar;30(3):772-784. doi: 10.1038/s41591-023-02785-8. Epub 2024 Jan 18.
2
Allogeneic natural killer cell therapy.异体自然杀伤细胞治疗。
Blood. 2023 Feb 23;141(8):856-868. doi: 10.1182/blood.2022016200.
3
Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-β.
在存在外源性转化生长因子-β(TGF-β)的情况下,用柔红霉素(DNR)共转导B7H3嵌合抗原受体自然杀伤细胞(CAR-NK细胞)可保留它们对胶质母细胞瘤(GBM)的细胞溶解功能。
Mol Ther Methods Clin Dev. 2022 Oct 21;27:415-430. doi: 10.1016/j.omtm.2022.10.010. eCollection 2022 Dec 8.
4
Natural killer cells in antitumour adoptive cell immunotherapy.肿瘤过继细胞免疫治疗中的自然杀伤细胞
Nat Rev Cancer. 2022 Oct;22(10):557-575. doi: 10.1038/s41568-022-00491-0. Epub 2022 Jul 25.
5
An in vitro platform supports generation of human innate lymphoid cells from CD34 hematopoietic progenitors that recapitulate ex vivo identity.体外平台支持从 CD34 造血祖细胞生成重现体外特征的人类先天淋巴细胞。
Immunity. 2021 Oct 12;54(10):2417-2432.e5. doi: 10.1016/j.immuni.2021.07.019. Epub 2021 Aug 27.
6
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.西达基奥仑赛,一种针对 B 细胞成熟抗原的嵌合抗原受体 T 细胞疗法,用于治疗复发或难治性多发性骨髓瘤患者(CARTITUDE-1):一项 1b/2 期开放标签研究。
Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.
7
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.伊达比星脂质体注射用多柔比星治疗复发/难治性多发性骨髓瘤
N Engl J Med. 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850.
8
The transcription factor ETS1 is an important regulator of human NK cell development and terminal differentiation.转录因子 ETS1 是人类 NK 细胞发育和终末分化的重要调节因子。
Blood. 2020 Jul 16;136(3):288-298. doi: 10.1182/blood.2020005204.
9
The Emerging Landscape of Immune Cell Therapies.免疫细胞疗法的新兴领域。
Cell. 2020 Apr 2;181(1):46-62. doi: 10.1016/j.cell.2020.03.001.
10
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.嵌合抗原受体修饰的自然杀伤细胞在 CD19 阳性淋巴肿瘤中的应用。
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.